CBiPES

CBiPES
Clinical data
ATC code	none;
Identifiers
	IUPAC name N-(4'-cyano-[1,1'-biphenyl]-3-yl-N-(3-pyridinylmethyl)ethanesulfonamide;
CAS Number	353235-01-5 ;
PubChem CID	9864510;
IUPHAR/BPS	3372;
ChemSpider	8040202;
CompTox Dashboard (EPA)	DTXSID70432071 ;
Chemical and physical data
Formula	C21H19N3O2S
Molar mass	377.46 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES N#Cc1ccc(cc1)-c(ccc2)cc2N(S(=O)(=O)CC)Cc3cccnc3;
	InChI InChI=1S/C21H19N3O2S/c1-2-27(25,26)24(16-18-5-4-12-23-15-18)21-7-3-6-20(13-21)19-10-8-17(14-22)9-11-19/h3-13,15H,2,16H2,1H3; Key:HDVYXILCBYGKGU-UHFFFAOYSA-N;

CBiPES is a drug used in scientific research that acts as a selective positive allosteric modulator for the metabotropic glutamate receptor group II subtype mGluR₂. It has potentially antipsychotic effects in animal models, and is used for researching the role of mGluR₂ receptors in schizophrenia and related disorders.^[1]^[2]^[3]

References

↑ Johnson MP, Barda D, Britton TC, Emkey R, Hornback WJ, Jagdmann GE, et al. (April 2005). "Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s)". Psychopharmacology. 179 (1): 271–83. doi:10.1007/s00213-004-2099-9. PMID 15717213. S2CID 2699540.
↑ Fell MJ, Katner JS, Johnson BG, Khilevich A, Schkeryantz JM, Perry KW, Svensson KA (March 2010). "Activation of metabotropic glutamate (mGlu)2 receptors suppresses histamine release in limbic brain regions following acute ketamine challenge". Neuropharmacology. 58 (3): 632–9. doi:10.1016/j.neuropharm.2009.11.014. PMID 19951716. S2CID 7262560.
↑ Sanger H, Hanna L, Colvin EM, Grubisha O, Ursu D, Heinz BA, et al. (March 2013). "Pharmacological profiling of native group II metabotropic glutamate receptors in primary cortical neuronal cultures using a FLIPR". Neuropharmacology. 66: 264–73. doi:10.1016/j.neuropharm.2012.05.023. PMID 22659090. S2CID 42448364.

This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Johnson MP, Barda D, Britton TC, Emkey R, Hornback WJ, Jagdmann GE, et al. (April 2005). "Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s)". Psychopharmacology. 179 (1): 271–83. doi:10.1007/s00213-004-2099-9. PMID 15717213. S2CID 2699540.

[2] Fell MJ, Katner JS, Johnson BG, Khilevich A, Schkeryantz JM, Perry KW, Svensson KA (March 2010). "Activation of metabotropic glutamate (mGlu)2 receptors suppresses histamine release in limbic brain regions following acute ketamine challenge". Neuropharmacology. 58 (3): 632–9. doi:10.1016/j.neuropharm.2009.11.014. PMID 19951716. S2CID 7262560.

[3] Sanger H, Hanna L, Colvin EM, Grubisha O, Ursu D, Heinz BA, et al. (March 2013). "Pharmacological profiling of native group II metabotropic glutamate receptors in primary cortical neuronal cultures using a FLIPR". Neuropharmacology. 66: 264–73. doi:10.1016/j.neuropharm.2012.05.023. PMID 22659090. S2CID 42448364.

[1]

[2]

[3]